---
schema_version: "secwatch.filing_event.v1"
accession: "0001770121-25-000009"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:36:09.084149+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology Q2 loss $0.39/sh (GAAP); positive type 1 diabetes cell therapy data; raises $105M

## Summary
- Net loss $93.8M ($0.39/sh GAAP); non-GAAP net loss $38.9M ($0.16/sh) vs $74.2M ($0.32/sh) year ago.
- Cash, cash equivalents & securities $72.7M at June 30; pro forma $177.2M including $105M raised in July/August 2025.
- Six-month data show transplanted HIP-edited islet cells survive & function (C-peptide+) without immunosuppression; NEJM published 12-week results.
- Expect to file IND for SC451 (iPSC-derived islet cell therapy) as early as 2026; FDA INTERACT meeting supports GMP master cell bank.
- Enrolling GLEAM (SC291 in autoimmune) & VIVID (SC262 in B-cell malignancies); data expected 2025; IND for SG299 in vivo CAR T as early as 2026.

## SEC filing metadata
- accession: 0001770121-25-000009
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000177012125000009/0001770121-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000177012125000009/sana-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770121-25-000009
- JSON: https://secwatch.observer/filing/0001770121-25-000009.json
- Plain text: https://secwatch.observer/filing/0001770121-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.